Baricitinib

Summary

Baricitinib (CHEMBL2105759) is an approved small-molecule antirheumatic drug (ATC L04AF02) targeting AAK1, BMP2K, and GAK; indicated across 33 conditions including rheumatoid arthritis and atopic eczema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L04AF02
• Targets: 7 (AAK1, BMP2K, GAK…)
• Indications: 33 conditions
• Clinical trials: 149
• Chemistry: 371.4 Da · C16H17N7O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105759
Name	Baricitinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	44205240
ChEBI	CHEBI:95341
ATC	L04AF02
Molecular formula	C16H17N7O2S
Molecular weight	371.4
InChIKey	XUZMWHLSFXCVMG-UHFFFAOYSA-N

SMILES: CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

IUPAC name: 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile

ChEBI definition: A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis.

Pharmacological roles (ChEBI): antirheumatic drug, EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, anti-inflammatory agent, immunosuppressive agent, antiviral agent.

Also known as: Baricitinib, Baricitinib phosphate, Baricitinib phosphate salt, INCB-028050, Incb-28050, INCB028050, LY-3009104, LY3009104, Olumiant, BARICITINIB, INCB-28050, 3JW

Patent coverage: 2,735 distinct patent families (6,741 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 6,446 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
AAK1	AP2 associated kinase 1	Inhibition	7.77	1.5%	Q2M2I8
BMP2K	BMP2 inducible kinase	Inhibition	7.4	0.1%	Q9NSY1
GAK	cyclin G associated kinase	Inhibition	6.87	42.3%	O14976
JAK1	Janus kinase 1	Inhibition	8.23	2.8%	P23458
JAK2	Janus kinase 2	Inhibition	8.15	0.7%	O60674
JAK3	Janus kinase 3	Inhibition	6.1	0.6%	P52333
TYK2	tyrosine kinase 2	Inhibition	7.21	0.8%	P29597

Broader ChEMBL bioactivity targets: 35 (assay-derived). Sample: Proto-oncogene tyrosine-protein kinase receptor Ret, Tyrosine-protein kinase JAK3, Casein kinase I isoform gamma-1, Casein kinase I isoform gamma-2, Calcium/calmodulin-dependent protein kinase type II subunit delta, Tyrosine-protein kinase JAK1, Tyrosine-protein kinase JAK2, Rho-associated protein kinase 2, Protein kinase C alpha type, Protein kinase C delta type.

Bioactivity

ChEMBL activities: 134 potent at pChembl ≥ 5 of 135 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
JAK1	9.15	IC50	0.7	nM	CHEMBL_ACT_26981419
JAK1	9.15	IC50	0.7	nM	CHEMBL_ACT_28111496
JAK1	9.15	IC50	0.7	nM	CHEMBL_ACT_28568324
JAK2	9.1	IC50	0.8	nM	CHEMBL_ACT_16480287
JAK1	9	IC50	0.99	nM	CHEMBL_ACT_16481193
JAK1	8.62	IC50	2.4	nM	CHEMBL_ACT_25452149
JAK2	8.54	IC50	2.9	nM	CHEMBL_ACT_25452161
JAK1	8.4	IC50	4	nM	CHEMBL_ACT_14751949
JAK1	8.4	IC50	4	nM	CHEMBL_ACT_16582342
JAK1	8.4	IC50	4	nM	CHEMBL_ACT_18106892
JAK1	8.4	IC50	4	nM	CHEMBL_ACT_23160394
JAK1	8.4	IC50	4	nM	CHEMBL_ACT_24872443
JAK2	8.4	IC50	4	nM	CHEMBL_ACT_26981422
JAK2	8.4	IC50	4	nM	CHEMBL_ACT_28111499
JAK2	8.4	IC50	4	nM	CHEMBL_ACT_28568327
JAK1	8.3	IC50	5	nM	CHEMBL_ACT_25452197
JAK2	8.26	IC50	5.5	nM	CHEMBL_ACT_28763564
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_18991826
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_18991850
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_23240775
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_24788499
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_24861800
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_24893916
JAK1	8.24	IC50	5.8	nM	CHEMBL_ACT_25535379
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_25535380
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_25555153
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_25701599
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_25848296
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_25851498
JAK2	8.24	IC50	5.7	nM	CHEMBL_ACT_26023216

Target pathways

Aggregated over 7 target gene(s): AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2.

Top Reactome pathways

91 total, by targets touching each:

Pathway	Targets	Genes
Interleukin-4 and Interleukin-13 signaling	4	JAK1, JAK2, JAK3, TYK2
Interleukin-20 family signaling	4	JAK1, JAK2, JAK3, TYK2
Potential therapeutics for SARS	4	JAK1, JAK2, JAK3, TYK2
Interleukin-6 signaling	3	JAK1, JAK2, TYK2
MAPK3 (ERK1) activation	3	JAK1, JAK2, TYK2
MAPK1 (ERK2) activation	3	JAK1, JAK2, TYK2
Cytokine Signaling in Immune system	3	JAK1, JAK2, JAK3
Signal Transduction	3	JAK1, JAK2, JAK3
Disease	3	JAK1, JAK2, JAK3
Immune System	3	JAK1, JAK2, JAK3
Signaling by Interleukins	3	JAK1, JAK2, JAK3
Interleukin-2 family signaling	3	JAK1, JAK2, JAK3
Interleukin-3, Interleukin-5 and GM-CSF signaling	3	JAK1, JAK2, JAK3
Infectious disease	3	JAK1, JAK2, JAK3
RAF/MAP kinase cascade	3	JAK1, JAK2, JAK3
MAPK family signaling cascades	3	JAK1, JAK2, JAK3
MAPK1/MAPK3 signaling	3	JAK1, JAK2, JAK3
IL-6-type cytokine receptor ligand interactions	3	JAK1, JAK2, TYK2
Interleukin-35 Signalling	3	JAK1, JAK2, TYK2
Interleukin-12 signaling	3	JAK1, JAK2, TYK2
Interleukin-27 signaling	3	JAK1, JAK2, TYK2
Interleukin receptor SHC signaling	3	JAK1, JAK2, JAK3
Signaling by CSF3 (G-CSF)	3	JAK1, JAK2, TYK2
SARS-CoV Infections	3	JAK1, JAK2, JAK3
Inactivation of CSF3 (G-CSF) signaling	3	JAK1, JAK2, TYK2
Viral Infection Pathways	3	JAK1, JAK2, JAK3
Activation of STAT3 by cadherin engagement	3	JAK1, JAK2, TYK2
RAF-independent MAPK1/3 activation	2	JAK1, JAK2
Interleukin-7 signaling	2	JAK1, JAK3
Interleukin-12 family signaling	2	JAK1, JAK2

Dominant GO biological processes

GO term	Targets
protein phosphorylation	7
cell surface receptor signaling pathway via JAK-STAT	4
cytokine-mediated signaling pathway	4
cell differentiation	4
intracellular signal transduction	4
growth hormone receptor signaling pathway via JAK-STAT	4
regulation of cell-cell adhesion	4
type II interferon-mediated signaling pathway	3
cellular response to virus	3
regulation of receptor signaling pathway via JAK-STAT	3
regulation of alpha-beta T cell activation	3
positive regulation of Notch signaling pathway	2
regulation of clathrin-dependent endocytosis	2
interleukin-15-mediated signaling pathway	2
interleukin-4-mediated signaling pathway	2

Indications & clinical

Indications

33 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
atopic eczema	3	MONDO:0004980	EFO:0000274
juvenile idiopathic arthritis	3	MONDO:0011429	EFO:0002609
alopecia areata	3	MONDO:0005340	EFO:0004192
uveitis	3	MONDO:0020283	EFO:1001231
pneumonia	3	MONDO:0005249	EFO:0003106
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
dermatomyositis	3	MONDO:0016367	EFO:0000398
juvenile dermatomyositis	3	MONDO:0008054	EFO:0000557
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915
influenza	3	MONDO:0005812	EFO:0007328
diabetic kidney disease	2	MONDO:0005016	EFO:0000401
psoriasis	2	MONDO:0005083	EFO:0000676
temporal arteritis	2	MONDO:0008538	EFO:1001209
primary biliary cholangitis	2	MONDO:0005388	EFO:1001486
myositis disease	2	MONDO:0021167	EFO:0000783
Sjogren syndrome	2	MONDO:0010030	EFO:0000699
vitiligo	2	MONDO:0008661	EFO:0004208
HIV infectious disease	2	MONDO:0005109	EFO:0000764
chronic kidney disease	2	MONDO:0005300	EFO:0003884
autoimmune thrombocytopenic purpura	2	MONDO:0008558	EFO:0007160
lichen planus	2	MONDO:0006572	EFO:1000726
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
mastitis	2	MONDO:0006849	EFO:1001034
subarachnoid hemorrhage	2	MONDO:0005099	EFO:0000713
brain injury	2	MONDO:0043510	MONDO:0043510
graft versus host disease	1	MONDO:0013730	MONDO:0013730
neuromyelitis optica	1	MONDO:0019100	EFO:0004256
allergic contact dermatitis	0	MONDO:0006525	EFO:1000668

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 149.

Phase distribution

Phase	Trials
PHASE2	45
PHASE3	43
PHASE1	21
Not specified	13
PHASE4	10
PHASE2/PHASE3	10
PHASE1/PHASE2	6
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05300932	PHASE4	ACTIVE_NOT_RECRUITING	A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
NCT05955066	PHASE4	RECRUITING	Effect of JAK Inhibitor on Erosion Healing in RA
NCT06687551	PHASE4	NOT_YET_RECRUITING	JAK Inhibitor Dose TAPering Strategy Study
NCT07357649	PHASE4	NOT_YET_RECRUITING	Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis
NCT03915964	PHASE4	COMPLETED	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT04086745	PHASE4	COMPLETED	A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04390464	PHASE4	UNKNOWN	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
NCT05080218	PHASE4	COMPLETED	COVID-19 VaccinE Response in Rheumatology Patients
NCT05660655	PHASE4	COMPLETED	Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis
NCT05827497	PHASE4	UNKNOWN	Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial
NCT02735707	PHASE3	RECRUITING	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT03414502	PHASE3	RECRUITING	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03773965	PHASE3	RECRUITING	A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03952559	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
NCT04088396	PHASE3	RECRUITING	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088409	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
NCT04381936	PHASE3	RECRUITING	Randomised Evaluation of COVID-19 Therapy
NCT04870203	PHASE3	ACTIVE_NOT_RECRUITING	Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04972760	PHASE3	RECRUITING	Baricitinib in Patients With Relapsing or naïve Dermatomyositis
NCT05651880	PHASE3	NOT_YET_RECRUITING	Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
NCT05723198	PHASE3	RECRUITING	A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT06475820	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
NCT06631287	PHASE3	RECRUITING	Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
NCT06768840	PHASE2/PHASE3	RECRUITING	Vitiligo, New Treatment and Serum s100B
NCT07222137	PHASE3	RECRUITING	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222332	PHASE3	RECRUITING	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07449910	PHASE2/PHASE3	NOT_YET_RECRUITING	Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
NCT07543458	PHASE3	NOT_YET_RECRUITING	Therapeutics for Moderate and Severe Dengue
NCT01710358	PHASE3	COMPLETED	A Study in Moderate to Severe Rheumatoid Arthritis
NCT01711359	PHASE3	COMPLETED	A Study in Participants With Moderate to Severe Rheumatoid Arthritis
NCT01721044	PHASE3	COMPLETED	A Moderate to Severe Rheumatoid Arthritis Study
NCT01721057	PHASE3	COMPLETED	A Study in Moderate to Severe Rheumatoid Arthritis Participants
NCT01885078	PHASE3	COMPLETED	An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
NCT02265705	PHASE3	COMPLETED	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
NCT03334396	PHASE3	COMPLETED	A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT03334422	PHASE3	COMPLETED	Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT03334435	PHASE3	COMPLETED	A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
NCT03428100	PHASE3	COMPLETED	A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
NCT03435081	PHASE3	COMPLETED	A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03559270	PHASE3	TERMINATED	A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

175 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
FEDRATINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
Gefitinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
MIDOSTAURIN	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
MOMELOTINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
PACRITINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
RUXOLITINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
SUNITINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
DOVITINIB	ChEMBL	Phase 3	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
LESTAURTINIB	ChEMBL	Phase 3	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
AT-9283	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
CC-401	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
R-406	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
SU-014813	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
TOZASERTIB	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
Idelalisib	PubChem	Approved	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3, TYK2
AXITINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK2, JAK3, TYK2
BOSUTINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK2, JAK3, TYK2
dacomitinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK3, TYK2
Entrectinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, JAK3
ERLOTINIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK2, JAK3, TYK2
Imatinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2, TYK2
FILGOTINIB	ChEMBL	Phase 4 (approved)	AAK1, BMP2K, JAK1, JAK2, JAK3, TYK2
NINTEDANIB	ChEMBL	Phase 4 (approved)	AAK1, BMP2K, JAK1, JAK2, JAK3, TYK2
UPADACITINIB	ChEMBL	Phase 4 (approved)	AAK1, GAK, JAK1, JAK2, JAK3, TYK2
DECERNOTINIB	ChEMBL	Phase 2	AAK1, BMP2K, JAK1, JAK2, JAK3, TYK2
Fostamatinib	PubChem	Approved	AAK1, BMP2K, GAK, JAK1, JAK2, TYK2
Trametinib	PubChem	Approved	AAK1, BMP2K, GAK, JAK1, JAK2, TYK2
Ceritinib	ChEMBL + PubChem	Phase 4 (approved)	BMP2K, GAK, JAK1, JAK2, JAK3
Ponatinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK1, JAK2
TOFACITINIB	ChEMBL + PubChem	Phase 4 (approved)	BMP2K, JAK1, JAK2, JAK3, TYK2
ALVOCIDIB	ChEMBL	Phase 3	AAK1, GAK, JAK2, JAK3, TYK2
PELITINIB	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK2, JAK3
TG100-115	ChEMBL	Phase 2	AAK1, BMP2K, GAK, JAK1, TYK2
Binimetinib	PubChem	Approved	AAK1, BMP2K, GAK, JAK1, TYK2
regorafenib	PubChem	Approved	AAK1, BMP2K, GAK, JAK1, TYK2
Dabrafenib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK2
DEUCRAVACITINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
Ibrutinib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK3
PALBOCICLIB	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK3
RITLECITINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
Sorafenib	ChEMBL + PubChem	Phase 4 (approved)	AAK1, BMP2K, GAK, JAK3
ABROCITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
DASATINIB	ChEMBL	Phase 4 (approved)	GAK, JAK2, JAK3, TYK2
PEFICITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
BREPOCITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
DELGOCITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
ITACITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
RUBOXISTAURIN	ChEMBL	Phase 3	AAK1, BMP2K, GAK, JAK3
ATINVICITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
AZD-1480	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
BMS-911543	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
CERDULATINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
GANDOTINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
GOLIDOCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
GUSACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
IFIDANCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2